Loading...
Market
What will be the market capitalization of Recursion Pharmaceuticals ($RXRX) by September 30, 2025?
3
Resolution / Starting Odds
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
NASDAQ stock market data and company financial reports
Story
Recursion Pharmaceuticals ($RXRX) Announces Positive Phase 2 Results for REC-994 in CCM
Sep 3, 2024, 12:08 PM
Recursion Pharmaceuticals ($RXRX) has announced positive Phase 2 topline results for REC-994, a first-in-disease investigational treatment for symptomatic cerebral cavernous malformation (CCM). The drug met its primary endpoint of safety and tolerability. Additionally, magnetic resonance imaging (MRI)-based secondary efficacy endpoints showed a trend towards reduced lesion volume. Despite these promising results, some investors remain cautious about the AI drug discovery developer's future prospects.
View original story
Similar markets
Below $2 billion • 25%
$2 billion to $4 billion • 25%
$4 billion to $6 billion • 25%
Above $6 billion • 25%
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%
Increase by 10% or more • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant increase • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No increase or decrease • 25%
Yes • 50%
No • 50%
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Yes • 50%
No • 50%
Partnership with a major pharmaceutical company • 25%
Acquisition by a major pharmaceutical company • 25%
Partnership with a tech company • 25%
No partnership or acquisition • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Top 50 • 25%
Top 100 • 25%
Top 200 • 25%
Below Top 200 • 25%